{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:39:35Z","timestamp":1792467575977,"version":"4.5.0"},"reference-count":116,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Follicular lymphoma (FL) is the second most common lymphoma subtype in Europe, with a median age at diagnosis of 60\u201365 years. It is generally considered an indolent disease, and the median overall survival at diagnosis now likely exceeds 20 years. However, considerable heterogeneity exists. Diagnosis requires adequate biopsy material and a specialized hematopathologist. Staging and prognosis rely on positron emission tomography (PET)\u2010computed tomography (CT). Prognostication at diagnosis is based on several validated clinical prognostic scores. Localized disease is usually treated with radiotherapy\u2009\u00b1\u2009Rituximab. The treatment of disseminated disease includes active surveillance (or in selected cases Rituximab monotherapy) for low\u2010tumor burden patients, and most often immunochemotherapy (or in selected cases chemo\u2010free therapeutic options), \u00b1antibody maintenance in high\u2010tumor burden patients. For relapsed or refractory disease, treatment with Rituximab\u2010Lenalidomide combination\u2009\u00b1\u2009Tafasitamab or Epcoritamab from the first relapse and single\u2010agent bispecific antibodies, chimeric antigen receptor T\u2010cell therapy (CAR\u2010T) cells, and Zanubrutinib\u2010Obinutuzumab after second relapse should be prioritized over immunochemotherapy. Given the long natural history and risk of relapse, careful follow\u2010up is an important part of patient management. Patients should be actively involved in decision\u2010making. In this guideline, we present current evidence\u2010based recommendations for diagnosis, staging, treatment, and follow\u2010up.<\/jats:p>","DOI":"10.1002\/hem3.70507","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:01:47Z","timestamp":1792465307000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow\u2010up"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-2681","authenticated-orcid":false,"given":"Marco","family":"Ladetto","sequence":"first","affiliation":[{"name":"Dipartimento di Medicina of Traslazionale Universit\u00e0 del Piemonte Orientale Alessandria Italy"},{"name":"IRCCS, Azienda Ospedaliero\u2010Universitaria Santi Antonio e Biagio e Cesare Arrigo Alessandria Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Bola\u00f1os","sequence":"additional","affiliation":[{"name":"Lymphoma Coalition Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bouguet","sequence":"additional","affiliation":[{"name":"ELLyE \u2013 Patient Organization Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6325-4193","authenticated-orcid":false,"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University Hospital of Heidelberg Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Department of Pathology University Hospital Schleswig\u2010Holstein Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Leppa","sequence":"additional","affiliation":[{"name":"University of Helsinki and Helsinki University Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Linton","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences The University of Manchester and The Christie NHS Foundation Trust Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Lopez\u2010Guillermo","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital Cl\u00ednic de Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"Hematology Azienda USL IRCCS of Reggio Emilia Reggio Emilia Italy"},{"name":"CHIMOMO Department University of Modena and Reggio Emilia Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) Lille, Universit\u00e9 de Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associ\u00e9es (ULR 7365\u2013GRITA) Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5044","authenticated-orcid":false,"given":"Jessica","family":"Okosun","sequence":"additional","affiliation":[{"name":"Centre for Haemato\u2010Oncology, Barts Cancer Institute Queen Mary University of London London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-3932","authenticated-orcid":false,"given":"Ewa","family":"Paszkiewicz\u2010Kozik","sequence":"additional","affiliation":[{"name":"Maria Sklodowska\u2010Curie National Research Institute of Oncology Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 &amp; Assistance Publique\u2010H\u00f4pitaux de Paris, H\u00f4pital Saint\u2010Louis, Hemato\u2010oncologie Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne Helene","family":"Tonino","sequence":"additional","affiliation":[{"name":"Department of Hematology Amsterdam UMC, Location VUmc Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-6073","authenticated-orcid":false,"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine, Charles University Hospital Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"Concord Repatriation General Hospital University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-0679","authenticated-orcid":false,"given":"Umut","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology Istanbul University \u2010 Cerrahpa\u015fa, Cerrahpa\u015fa Medical Faculty Istanbul T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III LMU University Hospital Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(15)00155-6","article-title":"Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B\u2010cell lymphoma: comparison between European population\u2010based data (EUROCARE\u20105)","volume":"2","author":"Mounier M","year":"2015","journal-title":"Lancet Haematol"},{"key":"e_1_2_14_3_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Program. Accessed February 15 2025.https:\/\/seer.cancer.gov\/seertools\/hemelymph\/51f6cf57e3e27c3994bd5357\/"},{"issue":"24","key":"e_1_2_14_4_1","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2022015520","article-title":"Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey","volume":"140","author":"Syrykh C","year":"2022","journal-title":"Blood"},{"issue":"7","key":"e_1_2_14_5_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"e_1_2_14_6_1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo E","year":"2022","journal-title":"Blood"},{"issue":"1","key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/modpathol.2012.127","article-title":"Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B\u2010cell characteristics","volume":"26","author":"Takata K","year":"2013","journal-title":"Mod Pathol"},{"issue":"11","key":"e_1_2_14_8_1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1200\/JCO.2010.32.9193","article-title":"Primary follicular lymphoma of the duodenum is a distinct mucosal\/submucosal variant of follicular lymphoma: a retrospective study of 63 cases","volume":"29","author":"Schmatz AI","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"e_1_2_14_9_1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2016-03-703819","article-title":"Genome\u2010wide analysis of pediatric\u2010type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene","volume":"128","author":"Schmidt J","year":"2016","journal-title":"Blood"},{"issue":"9","key":"e_1_2_14_10_1","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.V99.9.3376","article-title":"In situ localization of follicular lymphoma: description and analysis by laser capture microdissection","volume":"99","author":"Cong P","year":"2002","journal-title":"Blood"},{"issue":"2","key":"e_1_2_14_11_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B\u2010cell lymphomas of germinal\u2010center origin","volume":"42","author":"Morin RD","year":"2010","journal-title":"Nat Genet"},{"issue":"6","key":"e_1_2_14_12_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green MR","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_14_13_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.beha.2017.10.006","article-title":"Pathogenesis of follicular lymphoma","volume":"31","author":"Lackraj T","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"21","key":"e_1_2_14_14_1","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"Leval L","year":"2022","journal-title":"Blood"},{"issue":"22","key":"e_1_2_14_15_1","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first\u2010line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy C","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"e_1_2_14_16_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70207","article-title":"Large B\u2010cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow\u2010up","volume":"9","author":"Thieblemont C","year":"2025","journal-title":"HemaSphere"},{"key":"e_1_2_14_17_1","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non\u2010Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal\u2010Celigny P","year":"2004","journal-title":"Blood"},{"issue":"27","key":"e_1_2_14_19_1","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico M","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy E","year":"2018","journal-title":"Blood"},{"issue":"2","key":"e_1_2_14_21_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO-25-00892","article-title":"FLIPI24: a modern prognostic model and clinical trial enrichment tool for newly diagnosed follicular lymphoma","volume":"44","author":"Maurer MJ","year":"2026","journal-title":"J Clin Oncol"},{"issue":"27","key":"e_1_2_14_22_1","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first\u2010line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study","volume":"30","author":"Friedberg JW","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG\u2010PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari S","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"e_1_2_14_24_1","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1007\/s00259-024-06765-z","article-title":"End of induction [18F]FDG PET is prognostic for progression\u2010free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial","volume":"51","author":"Guerra L","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"e_1_2_14_25_1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.21.02301","article-title":"Relevance of bone marrow biopsies for response assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials","volume":"41","author":"Rutherford SC","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_2_14_26_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B\u2010cell lymphoma (DLBCL)","volume":"20","author":"Noy A","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"e_1_2_14_27_1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","article-title":"International benchmark for total metabolic tumor volume measurement in baseline 18F\u2010FDG PET\/CT of lymphoma patients: a milestone toward clinical implementation","volume":"65","author":"Boellaard R","year":"2024","journal-title":"J Nucl Med"},{"issue":"2","key":"e_1_2_14_28_1","first-page":"358","article-title":"The prognostic value of POD24 in relapsed\/refractory follicular lymphoma: a SCHOLAR\u20105 analysis","volume":"6","author":"Limbrick\u2010Oldfield EH","year":"2025","journal-title":"eJHaem"},{"issue":"23","key":"e_1_2_14_29_1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study","volume":"33","author":"Casulo C","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"e_1_2_14_30_1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo C","year":"2022","journal-title":"Blood"},{"issue":"1","key":"e_1_2_14_31_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non\u2010Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry L","year":"2011","journal-title":"Radiother Oncol"},{"issue":"20","key":"e_1_2_14_32_1","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2021004939","article-title":"Excellent response to very\u2010low\u2010dose radiation (4 Gy) for indolent B\u2010cell lymphomas: is 4 Gy suitable for curable patients?","volume":"5","author":"Imber BS","year":"2021","journal-title":"Blood Adv"},{"key":"e_1_2_14_33_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hon.70093_110","article-title":"High PFS with low infield recurrences after low dose radiotherapy and Obinituzumab in early\u2010stage nodal follicular lymphoma: final results of the GAZAI study (GLA 2018\u20103)","volume":"43","author":"Herfarth K.","year":"2025","journal-title":"Hematol Oncol"},{"issue":"11","key":"e_1_2_14_34_1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00066-024-02356-x","article-title":"PET\/CT\u2010based target volume definition in involved\u2010site radiotherapy for treatment of early\u2010stage nodal follicular lymphoma","volume":"201","author":"Wark A","year":"2025","journal-title":"Strahlenther Onkol"},{"key":"e_1_2_14_35_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105468","article-title":"Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early\u2010stage follicular lymphoma","volume":"110","author":"MacManus MP","year":"2024","journal-title":"EBioMedicine"},{"issue":"6","key":"e_1_2_14_36_1","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000160","article-title":"Rituximab with involved\u2010field irradiation for early\u2010stage nodal follicular lymphoma: results of the MIR Study","volume":"2","author":"Herfarth K","year":"2018","journal-title":"HemaSphere"},{"issue":"7","key":"e_1_2_14_37_1","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1016\/S2352-3026(24)00143-1","article-title":"Local radiotherapy and measurable residual disease\u2010driven immunotherapy in patients with early\u2010stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial","volume":"11","author":"Pulsoni A","year":"2024","journal-title":"Lancet Haematol"},{"issue":"31","key":"e_1_2_14_38_1","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low\u2013tumor burden follicular lymphoma in the rituximab era: results of an F2\u2010study database","volume":"30","author":"Solal\u2010C\u00e9ligny P","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_2_14_39_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16872","article-title":"The investigation and management of follicular lymphoma","volume":"191","author":"McNamara C","year":"2020","journal-title":"Br J Haematol"},{"key":"e_1_2_14_40_1","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low\u2010tumor\u2010burden follicular lymphomas between an initial no\u2010treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice P","year":"1997","journal-title":"J Clin Oncol"},{"key":"e_1_2_14_41_1","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicincontaining regimen with or without interferon alfa\u20102b for advanced follicular lymphomas: final analysis of survival and toxicity in the Grouped'Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal\u2010C\u00e9ligny P","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_14_42_1","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3235","article-title":"A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma","volume":"42","author":"Mozas P","year":"2024","journal-title":"Hematol Oncol"},{"key":"e_1_2_14_43_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long\u2010term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced\u2010stage non\u2010Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna K","year":"2003","journal-title":"Lancet"},{"key":"e_1_2_14_44_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch\u2010and\u2010wait approach in patients with advanced\u2010stage, asymptomatic, non\u2010bulky follicular lymphoma: an open label randomised phase 3 trial","volume":"15","author":"Ardeshna KM","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"e_1_2_14_45_1","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S2352-3026(25)00034-1","article-title":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long\u2010term results of a randomised, phase 3 trial","volume":"12","author":"Northend M","year":"2025","journal-title":"Lancet Haematol"},{"issue":"3","key":"e_1_2_14_46_1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bjh.19918","article-title":"Quality of life in advanced\u2010stage, asymptomatic, non\u2010bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful\u2010waiting","volume":"206","author":"Marzolini MAV","year":"2025","journal-title":"Br J Haematol"},{"key":"e_1_2_14_47_1","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event\u2010free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini M","year":"2004","journal-title":"Blood"},{"issue":"6","key":"e_1_2_14_48_1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced\u2010stage, follicular grade I non\u2010Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig TE","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_14_49_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00262","article-title":"Chemotherapy\u2010free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic Lymphoma Group trials with more than 10 years of follow\u2010up","volume":"36","author":"Lockmer S","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_2_14_50_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of 5 years after single\u2010agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03","volume":"34","author":"Taverna C","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"e_1_2_14_51_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta\u2010analysis","volume":"99","author":"Schulz H","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_14_52_1","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R\u2010CVP versus R\u2010CHOP versus R\u2010FM for the initial treatment of patients with advanced\u2010stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico M","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_14_53_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First\u2010line treatment of patients with indolent non\u2010Hodgkin lymphoma or mantle\u2010cell lymphoma with bendamustine plus rituximab versus R\u2010CHOP or R\u2010CVP: results of the BRIGHT 5\u2010year follow\u2010up study","volume":"37","author":"Flinn IW","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_14_54_1","first-page":"483","article-title":"Four versus two years of rituximab maintenance following bendamustine plus rituximab in first\u2010line follicular lymphoma: results of the randomized phase 3 study StiL NHL7\u20102008 MAINTAIN","volume":"130","author":"Rummel MJ","year":"2017","journal-title":"Blood"},{"issue":"7","key":"e_1_2_14_55_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response\u2010adapted postinduction strategy in patients with advanced\u2010stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari S","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"e_1_2_14_56_1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first\u2010line treatment of follicular lymphoma","volume":"377","author":"Marcus R","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"e_1_2_14_57_1","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann W","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"e_1_2_14_58_1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40273-018-0740-4","article-title":"Obinutuzumab in combination with chemotherapy for the first\u2010line treatment of patients with advanced follicular lymphoma: an evidence review group evaluation of the NICE Single Technology appraisal","volume":"37","author":"Thielen FW","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"e_1_2_14_59_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser F","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"e_1_2_14_60_1","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood.2026033126","article-title":"Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10\u2010year RELEVANCE trial analysis","volume":"147","author":"Gower N","year":"2026","journal-title":"Blood"},{"key":"e_1_2_14_61_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles G","year":"2011","journal-title":"Lancet"},{"key":"e_1_2_14_62_1","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression\u2010free survival benefit of rituximab maintenance in patients with follicular lymphoma: long\u2010term results of the PRIMA study","volume":"37","author":"Bachy E","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_2_14_63_1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s15010-023-02039-2","article-title":"Persistent SARS\u2010CoV\u20102 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab","volume":"51","author":"Franceschini E","year":"2023","journal-title":"Infection"},{"key":"e_1_2_14_64_1","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000529","article-title":"EHA\/ESMO Clinical Practice Guidelines for the management of malignant lymphoma: recommendations for the second phase of the COVID\u201019 pandemic","volume":"5","author":"Dreyling M","year":"2021","journal-title":"HemaSphere"},{"issue":"2","key":"e_1_2_14_65_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.35_2629","article-title":"NCRI PETREA trial: a phase 3 evaluation of PET\u2010guided, response\u2010adapted therapy in patients with previously untreated, advanced\u2010stage, high\u2010tumour\u2010burden follicular lymphoma","volume":"37","author":"Pettitt AR","year":"2019","journal-title":"Hematol Oncol"},{"issue":"12","key":"e_1_2_14_66_1","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2012-05-429514","article-title":"Pediatric\u2010type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement","volume":"120","author":"Louissaint A","year":"2012","journal-title":"Blood"},{"issue":"1","key":"e_1_2_14_67_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non\u2010Hodgkin lymphoma (ZUMA\u20105): a single\u2010arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson CA","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"e_1_2_14_68_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler NH","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"e_1_2_14_69_1","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser F","year":"2024","journal-title":"Nat Med"},{"issue":"19","key":"e_1_2_14_70_1","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B\u2010cell non\u2010Hodgkin lymphomas: extended follow\u2010up of a phase I\/II study","volume":"42","author":"Budde LE","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"e_1_2_14_71_1","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL\u20101): a phase 2 cohort of a single\u2010arm, multicentre study","volume":"11","author":"Linton KM","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"e_1_2_14_72_1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim TM","year":"2024","journal-title":"Ann Oncol"},{"issue":"33","key":"e_1_2_14_73_1","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani PL","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10524","key":"e_1_2_14_74_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(25)01778-7","article-title":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","volume":"407","author":"Sehn LH","year":"2026","journal-title":"Lancet"},{"issue":"10524","key":"e_1_2_14_75_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL\u20101): a global, open\u2010label, randomised, phase 3 trial","volume":"407","author":"Falchi L","year":"2026","journal-title":"Lancet"},{"issue":"2","key":"e_1_2_14_76_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.3163_T04","article-title":"MAHOGANY: a phase 3 trial of zanubrutinib plus anti\u2010CD20 versus lenalidomide plus rituximab in patients with relapsed\/refractory follicular or marginal zone lymphoma","volume":"41","author":"Sehn L","year":"2023","journal-title":"Hematol Oncol"},{"issue":"16","key":"e_1_2_14_77_1","doi-asserted-by":"crossref","first-page":"TPS7588","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7588","article-title":"CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received \u22651 line of systemic therapy","volume":"40","author":"Nastoupil LJ","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"e_1_2_14_78_1","doi-asserted-by":"crossref","first-page":"TPS7579","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7579","article-title":"ZUMA\u201022: a phase 3, randomized controlled study of axicabtagene ciloleucel (axi\u2010cel) versus standard\u2010of\u2010care therapy in patients with relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"41","author":"Flinn IW","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"e_1_2_14_79_1","doi-asserted-by":"crossref","first-page":"TPS7094","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7094","article-title":"Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed\/refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA\u20105)","volume":"42","author":"Vitolo U","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_14_80_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijrobp.2012.12.024","article-title":"Low\u2010dose involved\u2010field radiation in the treatment of non\u2010Hodgkin lymphoma: predictors of response and treatment failure","volume":"86","author":"Russo AL","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"e_1_2_14_81_1","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1016\/j.ijrobp.2010.10.013","article-title":"Palliation by low\u2010dose local radiation therapy for indolent non\u2010Hodgkin lymphoma","volume":"81","author":"Chan EK","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"e_1_2_14_82_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non\u2010inferiority trial","volume":"15","author":"Hoskin PJ","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"e_1_2_14_83_1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/cam4.4588","article-title":"The outcome of watchful waiting in patients with previously treated follicular lymphoma","volume":"11","author":"Fujino T","year":"2022","journal-title":"Cancer Med"},{"issue":"30","key":"e_1_2_14_84_1","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B\u2010cell non\u2010Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn LH","year":"2015","journal-title":"J Clin Oncol"},{"issue":"28","key":"e_1_2_14_85_1","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re\u2010treatment trial for low\u2010tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402","volume":"32","author":"Kahl BS","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"e_1_2_14_86_1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard JP","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_2_14_87_1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bjh.17045","article-title":"Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy\u2010free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"192","author":"Moccia AA","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"e_1_2_14_88_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B\u2010cell lymphoma receiving chimeric antigen receptor T\u2010cell therapy","volume":"42","author":"Iacoboni G","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"e_1_2_14_89_1","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B\u2010cell lymphoma (GALEN): a multicentre, single\u2010arm, phase 2 study","volume":"6","author":"Morschhauser F","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"e_1_2_14_90_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study","volume":"138","author":"Morschhauser F","year":"2021","journal-title":"Blood"},{"issue":"1","key":"e_1_2_14_91_1","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single\u2010centre, single\u2010arm, phase 2 trial","volume":"12","author":"Alderuccio JP","year":"2025","journal-title":"Lancet Haematol"},{"issue":"6","key":"e_1_2_14_92_1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow\u2010up study of 2 randomized trials from the German low grade lymphoma study group","volume":"24","author":"Jurinovic V","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"e_1_2_14_93_1","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High\u2010dose therapy improves progression\u2010free survival and survival in relapsed follicular non\u2010Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten HC","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_14_94_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.annonc.2023.10.095","article-title":"Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed\/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial","volume":"35","author":"Ladetto M","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"e_1_2_14_95_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70453","article-title":"Increased risk of secondary malignancies after autologous transplantation in R\/R follicular lymphoma: long\u2010term results from FIL\u2010FLAZ12 phase III trial","volume":"10","author":"Tavarozzi R","year":"2026","journal-title":"HemaSphere"},{"issue":"8","key":"e_1_2_14_96_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab\u2010refractory indolent non\u2010Hodgkin lymphoma (GADOLIN): a randomised, controlled, open\u2010label, multicentre, phase 3 trial","volume":"17","author":"Sehn LH","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"e_1_2_14_97_1","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non\u2010Hodgkin's lymphoma: long\u2010term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"Oers MHJ","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"e_1_2_14_98_1","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta\u2010analysis of randomized trials","volume":"103","author":"Vidal L","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"e_1_2_14_99_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single center experience","volume":"10","author":"Mozas P","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"e_1_2_14_100_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136228","article-title":"Efficacy outcomes of treatments for double relapsed\/refractory follicular lymphoma (R\/R FL): a systematic literature review","volume":"136","author":"Kahl BS","year":"2020","journal-title":"Blood"},{"issue":"1","key":"e_1_2_14_101_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2025-227","article-title":"Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed\/refractory follicular lymphoma","volume":"146","author":"Zinzani PL","year":"2025","journal-title":"Blood"},{"issue":"1","key":"e_1_2_14_102_1","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1182\/blood-2025-5352","article-title":"Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) after \u22652 prior therapies: 5\u2010year follow\u2010up of a pivotal Phase II study","volume":"146","author":"Budde E","year":"2025","journal-title":"Blood"},{"key":"e_1_2_14_103_1","first-page":"2077","article-title":"Efficacy of subcutaneous epcoritamab vs standard of care (SCHOLAR\u20105) in patients with relapsed\/refractory follicular lymphoma after \u22652 systemic therapies: an indirect treatment comparison","volume":"18","author":"Sureda A","year":"2024","journal-title":"HemaSphere"},{"issue":"14","key":"e_1_2_14_104_1","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/10428194.2023.2262066","article-title":"Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real\u2010world data in relapsed\/refractory follicular lymphoma in third or subsequent lines of systemic therapy","volume":"64","author":"McGough SF","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"e_1_2_14_105_1","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1182\/blood-2024-200865","article-title":"Matching\u2010adjusted indirect comparisons (MAICs) of odronextamab versus mosunetuzumab and epcoritamab for the treatment of patients with relapsed\/refractory follicular lymphoma (R\/R FL) after two or more lines of systemic therapy","volume":"144","author":"Jagadeesh D","year":"2024","journal-title":"Blood"},{"issue":"15","key":"e_1_2_14_106_1","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/bloodadvances.2024015274","article-title":"Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma","volume":"9","author":"Danilov AV","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"e_1_2_14_107_1","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood-2024-194627","article-title":"5\u2010Year follow\u2010up analysis from ZUMA\u20105: a phase 2 trial of axicabtagene ciloleucel (Axi\u2010Cel) in patients with relapsed\/refractory indolent non\u2010Hodgkin lymphoma","volume":"144","author":"Neelapu SS","year":"2024","journal-title":"Blood"},{"issue":"9","key":"e_1_2_14_108_1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jtct.2024.06.025","article-title":"Clinical practice recommendations for hematopoietic cell transplantation and cellular therapies in follicular lymphoma: a collaborative effort on behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation","volume":"30","author":"Iqbal M","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"e_1_2_14_109_1","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2022-162594","article-title":"CAR T\u2010cell therapy remain effective in patients with relapse\/refractory B\u2010cell non\u2010Hodgkin lymphoma after bispecific antibodies exposure: results of a Lysa Study based on the Descar\u2010T Registry","volume":"140","author":"Crochet G","year":"2022","journal-title":"Blood"},{"issue":"12","key":"e_1_2_14_110_1","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight\u2010year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri IF","year":"2008","journal-title":"Blood"},{"issue":"7","key":"e_1_2_14_111_1","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long\u2010term follow\u2010up from two prospective multicenter trials","volume":"95","author":"Pinana JL","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"e_1_2_14_112_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtct.2022.10.026","article-title":"Allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy in large B cell lymphoma","volume":"29","author":"Fried S","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"e_1_2_14_113_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high\u2010risk subgroups","volume":"10","author":"Batlevi CL","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"e_1_2_14_114_1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer MJ","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"e_1_2_14_115_1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.31128\/AJGP-07-19-4999","article-title":"Clinical oncology society of Australia position statement on cancer survivorship care","volume":"48","author":"Vardy JL","year":"2019","journal-title":"Aust J Gen Pract"},{"key":"e_1_2_14_116_1","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.13176","article-title":"Identifying the most prevalent unmet needs of cancer survivors in Australia: a systematic review","volume":"15","author":"Lisy K","year":"2019","journal-title":"Asia\u2010Pac J Clin Oncol"},{"issue":"3","key":"e_1_2_14_117_1","doi-asserted-by":"crossref","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow\u2010up","volume":"25","author":"Dreyling M","year":"2014","journal-title":"Ann Oncol"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:02:04Z","timestamp":1792465324000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/hem3.70507"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70507","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70507"}}